Related Experiment Video
Updated: Jul 18, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
J A Wagner1, S A Williams, C J Webster
1Merck & Co. Inc., Rahway, New Jersey, USA. wagner@merck.com
Abstract:
A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, "fit-for-purpose" evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model will distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Measurement of Bioavailability: Pharmacodynamic Methods
Clinical Trials: Overview
Preclinical Development: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacogenomics: Identification of New Drug Targets

